Andere talen Natera, Inc.

Aandelen

NTRA

US6323071042

Beurs gesloten - Nasdaq Andere beurzen 22:00:00 18-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
87,28 ^USD	-3,38%		-9,75%	+39,34%

18/04	Insider van Natera verkocht aandelen ter waarde van $7.265.651, volgens een recent SEC-document	MT
18/04	Insider van Natera verkocht aandelen ter waarde van $634.797, volgens een recente SEC filing	MT

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Natera Insider Sold Shares Worth $7,265,651, According to a Recent SEC Filing	18/04
Natera Insider Sold Shares Worth $634,797, According to a Recent SEC Filing	18/04
Natera Announces Publication of Largest Prospective dd-cfDNA Study in Kidney Transplantation	11/04
Natera, Inc. Announces Publication of Larger Prospective dd-cfDNA Study in Kidney Transplantation	11/04
Natera Announces New Data from Two Studies Extending the Clinical Validation of Its Prospera Heart dd-cfDNA Test for Heart Transplant Recipients	09/04
Natera Announces New Data From Two Studies Extending the Clinical Validation of Its Prospera™ Heart dd-cfDNA Test for Heart Transplant Recipients	08/04
Natera, Inc. Announces New Data from Two Studies Extending the Clinical Validation of Its Prospera Heartd-cfDNA Test for Heart Transplant Recipients	08/04
Natera Announces Positive Surveillance Analysis from the Randomized Phase III IMvigor011 Trial in Muscle-Invasive Bladder Cancer	08/04
North American Morning Briefing : Inflation Data, -2-	08/04
Natera Reports Positive Surveillance Analysis From Phase 3 Study of Bladder Cancer Test; Shares Rise	05/04
Natera Insider Sold Shares Worth $2,468,822, According to a Recent SEC Filing	05/04
Natera Announces Positive Surveillance Analysis from the Randomized Phase III IMvigor011 Trial in Muscle-Invasive Bladder Cancer	05/04
Natera and Alliance for Clinical Trials in Oncology Announce Activation of Alliance A032103, A Randomized, Phase II/III Adjuvant Trial in Urothelial Cancer	02/04
Natera and Alliance for Clinical Trials in Oncology Announce Activation of Alliance A032103 (MODERN): A Randomized, Phase II/III Adjuvant Trial in Urothelial Cancer	01/04
Natera, Inc. and Alliance for Clinical Trials in Oncology Announce Activation of Alliance A032103 A Randomized, Phase Ii/Iii Adjuvant Trial in Urothelial Cancer	01/04
Natera Announces Phase III Randomized CIRCULATE Trial in France, Evaluating Signatera™ in Stage II Colorectal Cancer	18/03
Natera, Inc. Announces Phase III Randomized CIRCULATE Trial in France, Evaluating Signatera?? in Stage II Colorectal Cancer	18/03
Natera, Inc. - New KDIGO Guideline Supports Genetic Testing for the Majority of CKD Patients to Establish Cause of Disease	15/03
New KDIGO Guideline Supports Genetic Testing for the Majority of CKD Patients to Establish Cause of Disease	14/03
Natera to Present New Data at the 2024 SGO Annual Meeting on Women's Cancer, Following Recent Medicare Coverage Decisions in Ovarian and Breast Cancers	13/03

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Natera, Inc.

Aandelen

NTRA

US6323071042

Andere talen

Filters